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HEMODYNAMICS/SHOCK/ASSIST DEVICES
o non.lynchronized mode
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Reduction in tl2-Receptor Autoantibody Level in
Patients with Idiopathic Dilated Cardiomyopathy
During Mechanical Cardiac Assist System
Support
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Conclusion: Mechanical cardiac assist device support not only leads to
an improvement in the hemodynamic condition of pts, but apparently also
In immunological changes, such as a diminished presentation of specific
antigens and a consecutive reduction of autoantibodies, which in the future
may be important in assessing the indication for weaning from cardiac assist
devices instead of performing transplantation.
Johannes Muller, Gerd Wallukat 1, Henryk Siniawski, Yougo Weng, Roland Hetzer.
German Heart Institute, Berlin, Germany; 1 Max De/brOck Center- Berlin, Germany
Ten patients (pts) with idiopathic dilated cardiomyopathy were implanted
with mechanical left ventricular assist devices (Novacor, TCI) as a bridge to
transplantation. The following pre-implantation data was observed: right and
left ventricular ejection fraction <20%, x-ray heart-lung ratio >0.68, left ven-
tricular diameter>7.9 cm, and central venous pressure >25 mmHg. All pts
were in NYHA class IV and at least on a medium dose of catecholamines.
tJrreceptor autoantibody (RAAB) levels were measured by bioassay before
implantation and once a week postoperatively. All pts clinically recovered
within 6-8 weeks, RAABs were not detected in two pts while in eight pts
who preoperatively exhibited a relative level of 25 ± 8 the level decreased
during the ensuing 14 weeks to zero in 6 pts. These 6 pts were supported
with a device which operated synchronously with the patient's heart rate
thus leading to optimal reduction in the afterload of the left ventricle (Fig.l.
The RAAB level decreased more gradually in the other 2 pts reaching zero
three weeks later. A non-synchronized device which did not provide the same
degree of afterload reduction was implanted in these pts (Fig.1. Although they
exhibited a reduction in RAABs and heart rate, a significant improvement in
cardiac function, and a decrease in heart size, the two pts with no detectable
RAABs exhibited neither an improvement in c2rdiac function nor a reduction
in cardiac diameter.
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ditivity, and less than unity when suggesting antagonism. The synergy index
was 0.66 (95% confidence interval 0.46 to 0.94) for mortality at the end of
the study, and 0.68 (0.44 to 1.04) for 30-day mortality, indicating antagonism
between enalapril and ASA. No significant interaction was found regarding
nonfatal major events.
Conclusion: We found evidence of enalapril-ASA interaction. Excess mor-
talityoccurred when enalapril was randomized to patients using ASA at base-
line.
Before LVAD 1wk post 8 wks post Normals
MAP 65 ± 4 93 ± 6* 92 ± 5* 89 ± 9
Peak FBF 5.9 ± 16 95 ± 4.8 16.4 ± 2.8* 31.5 ± 2.71
Conductance 010 ± 0.03 0.10 ± 0.05 0.18 ± 0.03* 0.36 ± 0.05f
EDV(cc) EF(%) COIUmin) RFI%)
PreOp 317 ± 111 18 ± 5 3.1 ± 1.0 70 ± 12
PestOp 291 ± 106 24 ± 9 4.6 ± 0.8 13 ± 10
A -26 ± 31 +6 ± 5 +15 ± 0.9 -57 ± 15
P 0.04 0.02 0004 <0.001
* indicates p < 0.05 vs. Before LVAD, 1 indicates p < 005 vs. 8 wks post-LVAD
Mean CO increased from 2.3 IImin before LVAD to 5.4 l/min 1 and 8 wks
during LVAD support. Despite early normalization of CO and MAP within 1
week after LVAD, the maximum vascular conductance after brachial artery
occlusion did not change after 1week, and remained less than that observed
in normal subjects after 8 weeks of LVAD support. The delayed and incom-
plete reversal of abnormal metabolic vasodilation during long-term contin-
uous LVAD support suggests that mechanisms in addition to reduced CO
contribute to decreased metabolic vasodilation in patients with CHE
Mitral regurgitation (MR) frequently complicates cardiomyopathy (CM) and
contributes to symptoms of congestive heart failure (CHF). This study was
undertaken to assess the changes in CHF and left ventricular (LVI systolic
performance following mitral valve reconstruction (MVR) in patients with se-
vere MR secondary to end-stage dilated CM. Nine consecutive patients (age
64 ± 10 yrs) with severe LV dysfunction (ejection fraction [EFI 18 ± 5% [10-
25%]). severe MR and NYHA Class III (n = 1) or IV (n = 8) CHF despite ag-
gressive medical therapy undervvent MVR. All patients were receiving ther-
apy including digoxin, diuretics and afterload reducers. Two patients were
awaiting heart transplantation.
There were no operative deaths or deaths on 17 ± 5 (8-24) week follow-
up (PostOp). All patients noted symptomatic improvement NYHA Class im-
proved from 3.9 ± 0.3 pre-operatively (PreOp) to 1.7 ± 0.5 (p < 0.001) Di-
uretic requirements were markedly lower for 5 of 9 patients and stable for
the remaining 4. Ouantitative 2D echo/Dopplerwas performed on all patients
PreOp and on 8 of 9 patients PostOp. MR was absent or mild on follow-up in
all. Matched PreOp and PostOp LV end-diastolic volume (EDVL EF. forward
cardiac output (CO) and regurgitant fraction (RF) were compared for change
(6.):
Improvement in CHF occurred after MVR in all patients on short-term
follow-up, accompanied by lower LV end-diastolic volume and increased EF
and forvvard cardiac output Mitral reconstruction may be a new strategy for
the treatment of patients with severe MR complicating end-stage cardiomy-
opathy.
pressure (MAP, mmHg) was measured during each FBF measurement in the
contralateral arm by cuff method. MAP, peak FBF. and maximum vascular
conductance (calculated in arbitrary units as FBF/MAP) after arterial occlu-
sion were as follows:
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Early Improvement in Congestive Heart Failure
Following Correction of Secondary Mitral
Regurgitation in End-Stage Cardiomyopathy
David S. Bach, William F. Armstrong, Steven F. Bolling. University of Michigan, Ann
Arbor, MI
Lloyd A. Marks, Anthony J. Groch. Temple University Department of Pediatrics, St.
Christopher's Hospital for Children, Philadelphia, PA
Hypovolemic shock is difficult to recognize in its early stages because clin-
ically significant changes in heart rate (HRl. blood pressure (BPl. and urine
output occur late in its course. This study was conducted to determine if
changes in peripheral pulse volume (PV) occur early in acute blood loss, prior
to clinically significant changes in HR or BP PV is defined as the maximum
change in volume of a limb segment (e.g. calf) occuring during the cardiac
cycle and is measured noninvasively with a digitally enhanced admittance
plethysmograph. HR, systolic BP (SBP), diastolic BP (DBP), and calf PV (in
microliters, JlL) were measured in 35 male blood donors (age = 38.7 ± 11.1
[sd] yrs, weight = 87.7 ± 15.3 [sd] kg) before and after donating a unit of
whole blood (the average blood loss was 5.3 ± 0.9 [sd] mllkg). Pre and post
donation measurements were compared using paired Student's t-test. The
results (mean ± se) are tabulated below and illustrated above:
Antagonism Between Enalapril and Aspirin:
Subgroup Analysis of the Cooperative New
Scandinavian Enalapril Survival Study II
(CONSENSUS II)
Khang N. Nguyen, Ivar Aursnes, Steve Snapinn, John Kjekshus. University of Oslo
and National Hospital, Oslo, Norway
Several drugs have been investigated regarding their effect on mortality
when given early after an acute myocardial infarction. The use of angiotensin-
converting enzyme (ACE) inhibitors has been studied in several trials with in-
consistent results. Aspirin (ASA) has become a well documented therapeutic
adjunct in patients with coronary heart disease. Attention has recently been
focused on a possible interaction between aspirin and ACE inhibitors. We
therefore reanalyzed data from the CONSENSUS II to find any evidence of
differential effects of the ACE inhibitor enalapril in subgroups defined by use
of ASA at baseline.
Stepwise logistic regression tested the multiplicative interaction. The
enalapril-ASA interaction term was a significant predictor of at the end of
the study (odds ratio 1.442, p ~ 0.047), and was a borderline-significant pre-
dictor of mortality 30 days after randomization (odds ratio 1.450, p = 0.085).
We used Rothman synergy index S to examine the postulated interaction
with departure from an additive model. S would be equal to unity under ad-
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Association of a Molecular Variant of the
Angiotensinogen Gene and Hypertension
Vasan S. Ramachandran, Daniel Levy, Martin G. Larson, Jose M. Ordovas, Ernst
J. Schaefer, Richard H. Myers, Klaus Lindpaintner, Peter w.F. Wilson. Framingham
Heart Study, Framingham, MA
Clinical
status
Mild HTNI%)
Severe HTN 1%)
1901-811
A molecular variant of the angiotensinogen gene encoding methionine in-
stead of threonine at position 174 (T174M) has been associated with essen-
tial hypertension (HTN) in case-control studies. We examined the relations of
the T174M allele with HTN in 1401 subjects (707 men, 694 women) from the
Framingham Offspring Study (mean age 50.5, range 25-78 years). Pooled-
and sex-specific simple association analyses revealed no relation between
hypertension status and presence or absence of T174M. Conditional logistic
regression was used to analyze the relations of T174M to HTN in 143 sib-
ships in which at least 1 sibling had HTN. After adjusting for sex and age,
presence of T174M was associated with a nonsignificant increase in proba-
bility of HTN (OR 1.89, 95% CI 0.83-4.29, P = 0.13). Analysis of 25 affected
sibling-pairs with severe HTN suggested an excess sharing of the T174M
allele (p = 0.056).
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gaps. The two populations had similar systolic and diastolic blood pressures,
serum lipid levels and smoking history. Logistic regression analysis including
age in the model indicated that only female gender, beta (an index of arte-
rial stiffness) and the presence of plaque were independently related to the
presence of auscultatory gaps. This study provides the first evidence that
auscultatory gaps are related to the presence of carotid atherosclerosis and
to increased arterial stiffness in hypertensive patients, independently of age.
Although these observations need to be confirmed by prospective studies
they suggest a prognostic relevance of the auscultatory gaps.
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Pre-Donation Post-Donation Change Significance
HRI/min) 68.5 ± 1.5 69.8 ± 1.5 1.4 ± 0.6 p < 0.02
SBP(mmHg) 143.1 ± 2.5 1458 ± 3.1 2.9 ± 2.3 n.s
DBP(mmHg) 732 ± 2.0 75.7 ± 1.7 1.9 ± 1.5 n.s.
PVIJ.!LI 1151 ± 64 954 ± 39 -197 ± 53 p < 0.0001
There were no significant changes in either SBP or DBR The HR increased
significantly, but by only 2.0% (p < 0.02). The PV decreased by 17.1 % (p <
0.0001), which is 8.6 times greater than the percent change in heart rate (p
< 0.01). The PV decrease correlated with the blood loss per kg (r = 0.46, p
< 0.01). We conclude that a significant change in PV occurs with relatively
minor blood loss. Pulse volume analysis may therefore provide an early indi-
cation of hypovolemia due to acute blood loss.
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Borderline Isolated Systolic Hypertension and
Subsequent Risk of Cardiovascular Disease
Christopher J. O'Donnell, Paul M. Ridker, Klaus Berger, Frances LaMotte, Robert
J. Glynn, JoAnn E. Manson, Charles H. Hennekens. Division of Preventive Medicine,
Brigham and Women's Hospital, Boston, MA
1901-801
Mean 195% CII* P < 0.05. ** P< 0.01, STD = ST Segment Depression
ISCHEMIC HEART DISEASE - CHRONIC/SILENT ISCHEMIA
AA = normal. Aa ~ presence of 1T174M allele, aa = presence of 2T174M alleles. Severe
HTN = systolic BP ~ 160 mmHg or diastolic BP ~ 100 mmHg or use of ~2 anti-HTN
medications. Mild HTN ~ systolic BP ~ 140 mmHg or diastolic BP ~ 90 mmHg or use of
a single anti-HTN medication.
Ranolazine Dose Group minus Placebo Group Responses
267 mg tid 400 mg bid 400 mg tid
231 S,38)** 19( 4, 34)* 19 ( 4, 341*
1212,23) 10(-06,20) 10{-01,201
25111,39)** 17( 3. 31)* 22( 8, 361**
1.1% -0.3% 1.9%
A Multicenter Controlled Trial of a Novel
Metabolic Active Compound (Ranolazine) in
Chronic Stable Angina Patients
Conclusions: In this large noninstitutionalized sample, we did not find an
association between the T174M allele and HTN. In a subset of 25 sibships
with severe HTN, however, genetic linkage between the angiotensinogen
locus and severe HTN was suggested.
Time to angina
Exercise duration
Time to 1mm ST
% with adverse event
Parameter (in sec.)
Ranolazine significantly increased times to onset of both angina and ST
segment depression at all doses tested. All exercise parameters were sig-
nificantly (P :5 0.01) improved with ranolazine at peak plasma levels com-
pared with placebo as ranolazine plasma levels ranged from 1,350 to 2,130
William B. Smith, Steven Chrysant, William 1. Garland, Thomas S. Parker, Howard
1. Walpole, Ahmad Mokatrin 1, Daniel Gennevois 1, Carl J. Pepine, Syntex
Ranolazine Study Group. University ofFlorida, Gainesville, FL
Ranolazine is a new antianginal agent believed to reduce oxygen demand
through its metabolic action without effects on blood pressure, heart rate
or cardiac function. It was evaluated in a randomized, double-blind, placebo-
controlled, crossover trial with an extended-period Latin square design (5
one week periods). During a placebo phase, 312 patients with chronic stable
angina (:::3 months) receiving multiple antianginals were withdrawn from::: 1
antianginal drugs. After their exercise time had shortened by :::1.0 mins they
were randomized to receive either ranolazine 267 mg tid, 400 mg bid, 400 mg
tid or placebo during each study period. After 1 week of treatment exercise
tolerance (Bruce protocol) and plasma ranolazine levels were measured at
peak (1 hr after dosing) and at trough (8 [tid] or 12 [bid] hr after dosing).
Results at Peak Ranolazine Blood Level
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Auscultatory Gaps and Target Organ Damage in
Hypertensive Patients
M. Chiara Cavallini, Mary J. Roman, Seymour G. Blank, Riccardo Pini, Thomas
G. Pickering, Richard B. Devereux. The New York Hospital-Cornell University Medical
Center, New York, NY
Guidelines are unclear about treatment of borderline isolated systolic hyper-
tension, defined as both systolic BP 140-159 mmHg and diastolic BP < 90
mmHg. We investigated the association between borderline isolated sys-
tolic hypertension and subsequent risk of myocardial infarction (MI), stroke,
cardiovascular death, and the combined endpoint of important cardiovas-
cular events (nonfatal MI, nonfatal stroke or cardiovascular death) among
22,071 men age 40-84 years followed prospectively for an average of 10.7
years in the Physician's Health Study. Baseline BP and cardiovascular risk fac-
tors were available from completed questionnaires on 16,678 men among
whom 960 subsequently had an incident important cardiovascular event. In
proportional hazards models adjusting for other cardiovascular risk factors,
the relative risks were calculated for those with borderline isolated systolic
hypertension relative to those with both systolic BP < 140 mmHg and dias-
tolic BP < 90 mmHg. These relative risks were 1.05 (95% confidence interval
CI 0.80 to 1.36) for MI, 1.68 (95% CI 1.24 to 2.26) for stroke, 1.61 (95% CI
1.19 to 2.18) for cardiovascular death, and 1.32 (95% CI 1.11 to 1.58) for the
combined endpoint of important cardiovascular events. These associations
were not altered by an analysis excluding participants who reported baseline
treatment for hypertension.
Conclusion: Borderline isolated systolic hypertension is associated with a
significantly increased risk of subsequent important cardiovascular events.
Auscultatory gaps are a common finding in clinical practice but their clinical
and prognostic importance has never been assessed. To examine the rela-
tion of auscultatory gaps to left ventricular and arterial structure and function,
wideband external pulse recordings during cuff deflation to detect ausculta-
tory gaps and ultrasonographic examination of left ventricle and extracranial
carotid artery were performed in 168 unmedicated, asymptomatic hyperten-
sive subjects. Vascular stiffness was also evaluated by simultaneous carotid
pressure waveforms obtained by applanation tonometry of the contralateral
carotid artery. Auscultatory gaps were present in 21 % of the population and
were associated with older age (64 ± 11 vs 55 ± 13 years, p < 0.0005). fe-
male gender (66 vs 44%, p < 0.05) and increased arterial stiffness (beta = 8.5
± 4.6 vs 5.8 ± 3.2, P < 0.005). Differences in arterial stiffness persisted after
controlling for the confounding effects of age and gender. The prevalence of
atherosclerotic plaques was more than two-fold increased among subjects
with gaps (50 vs 22%, p < 0.005). No significant differences were found in
left ventricular structure and function between the subjects with and without
